Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

To compare these regimens to conventional 30 : 70 premixture on a twice a day basis.

Who Took Part

The abstract describes 2 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This randomized, double-blind, two-period crossover study included 16 patients with type 2 diabetes.

Twenty four-hour serum glucose and insulin profiles were obtained thrice: (1) after a one-week run-in period with biphasic human insulin (BHI) 30/70 twice daily (run-in), (2) after 4 weeks of treatment with thrice daily BIAsp 70 before breakfast, lunch and dinner (Dinner70 regimen) and (3) after 4 weeks of BIAsp 70 before breakfast and lunch and BIAsp 50 before dinner (Dinner50).

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The patients were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

As a double-blind Insulin Aspart study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

The methods mention a period of one week.

What Was Measured

PubMed files the paper under topics including Blood Glucose, C-Peptide, Circadian Rhythm, Diabetes Mellitus, Type 2, Fasting, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 2 patients over one week.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page.